Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease

  • Victor L. Villemagne
  • Rachel S. Mulligan
  • Svetlana Pejoska
  • Kevin Ong
  • Gareth Jones
  • Graeme O’Keefe
  • J. Gordon Chan
  • Kenneth Young
  • Henri Tochon-Danguy
  • Colin L. Masters
  • Christopher C. Rowe
Original Article

DOI: 10.1007/s00259-012-2088-x

Cite this article as:
Villemagne, V.L., Mulligan, R.S., Pejoska, S. et al. Eur J Nucl Med Mol Imaging (2012) 39: 983. doi:10.1007/s00259-012-2088-x

Abstract

Purpose

Amyloid imaging with 18F-labelled radiotracers will allow widespread use of this technique, facilitating research, diagnosis and therapeutic development for Alzheimer’s disease (AD). The purpose of this analysis was to compare data on cortical Aβ deposition in subjects who had undergone both 11C-PiB (PiB) and 18F-florbetaben (FBB) PET imaging.

Methods

We identified ten healthy elderly controls (HC) and ten patients with AD who had undergone PET imaging after intravenous injection of 370 MBq of PiB and 300 MBq of FBB under separate research protocols. PiB and FBB images were coregistered so that placement of regions of interest was identical on both scans and standard uptake value ratios (SUVR) using the cerebellar cortex as reference region were calculated between 40 and 70 min and between 90 and 110 min after injection for PiB and FBB, respectively.

Results

Significantly higher SUVR values (p < 0.0001) in most cortical areas were observed in AD patients when compared with HC with both radiotracers. Global SUVR values in AD patients were on average 75% higher than in HC with PiB and 56% higher with FBB. There was an excellent linear correlation between PiB and FBB global SUVR values (r = 0.97, p < 0.0001) with similar effect sizes for distinguishing AD from HC subjects for both radiotracers (Cohen’s d 3.3 for PiB and 3.0 for FBB).

Conclusion

FBB, while having a narrower dynamic range than PiB, clearly distinguished HC from AD patients, with a comparable effect size. FBB seems a suitable 18F radiotracer for imaging AD pathology in vivo.

Keywords

Alzheimer’s diseaseAmyloid imagingPositron emission tomography

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Victor L. Villemagne
    • 1
    • 2
    • 3
  • Rachel S. Mulligan
    • 1
  • Svetlana Pejoska
    • 1
  • Kevin Ong
    • 1
  • Gareth Jones
    • 1
  • Graeme O’Keefe
    • 1
  • J. Gordon Chan
    • 1
  • Kenneth Young
    • 1
  • Henri Tochon-Danguy
    • 1
  • Colin L. Masters
    • 3
  • Christopher C. Rowe
    • 1
    • 2
  1. 1.Department of Nuclear Medicine and Centre for PETAustin HealthHeidelbergAustralia
  2. 2.Department of MedicineUniversity of MelbourneParkvilleAustralia
  3. 3.The Mental Health Research Institute of VictoriaParkvilleAustralia